Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

Neurobiology of Aging

Volumn 23, Issue 6, 2002, Pages 991-1000

  Lemere, Cynthia A ^a   Spooner, Edward T ^a   Leverone, Jodi F ^a   Mori, Chica ^a   Clements, John D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A immunization; AD vaccine; Alzheimer's disease; E. coli heat labile enterotoxin (LT); Intranasal (i.n.); LT(R192G); PDAPP; PSAPP

Indexed keywords

ADJUVANT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; VACCINE;

ALZHEIMER DISEASE; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REDUCTION; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; BACTERIAL TOXINS; BRAIN; CELL LINE; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; IMMUNOTHERAPY; MALE; MICE; NASAL MUCOSA; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SPECIES SPECIFICITY;

EID: 0036860352     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00127-6     Document Type: Article

References (67)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
2. Backsai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P.et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7(3):2001;369-372.
3. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL). Formulations for the next generation of vaccines. METHODS. 19:1999;103-107.
4. Baldridge J.R., Yorgensen Y., Ward J.R., Ulrich J.T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine. 18(22):2000;2416-2425.
5. Ball J., Hardy M., Atmar R., Conner M., Estes M. Oral immunization with recombinant Norwalk virus-like particles induces a mucosal immune response in mice. J. Virol. 72:1998;1345-1353.
6. Barackman J.D., Ott G., O'Hagan T. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect. Immun. 67(8):1999;4276-4279.
7. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid-beta peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8):2000;916-919.
8. Belyakov I., Ahlers J., Clements J., Strober W., Bersofsky J. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J. Immunol. 165:2000;6454-6462.
9. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J.et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7(12):2001;1320-1326.
10. Ben-Yedidia T., Marcus H., Reisner Y., Arnon R. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int. Immunol. 11(7):1999;1043-1051.
11. Berstad A.K., Oftung F., Korsvold G.E., Haugen I.L., Froholm L.O., Holst J.et al. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine. 18(22):2000;2323-2330.
12. Brayden D., Templeton L., McClean S., Barbour R., Huang J., Nguyen M.et al. Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered β-amyloid in mice. Vaccine. 19:2001;4185-4193.
13. Cardenas-Freytag L., Cheng E., Mayeux P., Domer J.E., Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun. 67(2):1999;826-833.
14. Cheng E., Cardenas-Freytag L., Clements J. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine. 18:1999;38-49.
15. Choi A., Basu M., McNeal M., Clements J., Ward R. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J. Virol. 73:1999;7574-7581.
16. Choi A., Basu M., McNeal M., Flint J., VanCott J., Clements J.et al. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein [in process citation]. J. Virol. 74:2000;11574-11580.
17. Chong C.M., Friberg M., Clements J.D. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Esherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 16:1998;732-740.
18. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 6:1988;269-277.
19. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M.et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J Immunol 1999 March 1;162(5):3103]. J. Immunol. 160(2):1998;870-876.
20. Del Giudice G., Pizza M., Rappuoli R. Mucosal delivery of vaccines. Methods. 19(1):1999;148-155.
21. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63(5):1995;1617-1623.
22. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M.et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as non-toxic, mucosal adjuvants. Proc. Natl. Acad. Sci. U.S.A. 92(5):1995;1644-1648.
23. Elson C. Cholera toxin and its subunits as potential oral adjuvants. Immunol. Today. 146:1989;29-33.
24. Frenkel D., Katz O., Solomon B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. U.S.A. 97(21):2000;11455-11459.
25. Gerber S., Lane C., Brown D., Lord E., DiLorenzo M., Clements J.et al. Human papillomavirus virus-like particles are efficient oral immunogens whe coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 75:2001;4752-4760.
26. Gluck U., Gebbers J-O., Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73(9):1999;7780-7786.
27. Guillobel H., Carinhanha J., Cardenas L., Clements J., de Almeida D., Ferreira L. Adjuvant activity of a non-toxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Samonella enteric serovar Typhimurium vaccine strain. Infect. Immun. 68:2000;4349-4353.
28. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K.et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing trace amount of the holotoxin. Vaccine. 14:1996;113-119.
29. Hathaway L., Partidos C., Vohra P., Steward M. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Vaccine. 13:1995;1495-1500.
30. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D.et al. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature. 408(6815):2000;979-982.
31. Katz, J, Lu, X, Galphin, J, Clements, J. Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination. In: Brown L, Hampson A, Webster R, editors. Options for the Control of Influenza. 3rd Ed. New York: Elsevier; 1996, p. 292-7.
32. Katz J., Lu X., Young S., Galphin J. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated virus vaccine. J. Infect. Dis. 175:1997;352-363.
33. Kotloff K., Sztein M., Wasserman S., Losonsky G., DiLorenzo S., Walker R. Safety and immunogenicity of oral inactivated whole cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69:2001;3581-3590.
34. Kuper C.F., Koornstra P.H., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M.et al. The role of nasopharyngeal lymphoid tissues. Immunol. Today. 13(6):1992;219-224.
35. Langermann S., Palaszynski S., Sadziene A., Stover C.K., Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorteri. Nature. 372:1994;552-555.
36. Lee C. Vaccination against Helicobacter pylori in non-human primate models and humans. Scand. J. Immunol. 53:2001;437-442.
37. Lee C., Weltzin R., Thomas W., Kleanthous H., Ermak T., Soman G.et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challange with Helicobacter felis. J. Infect. Dis. 172:1995;161-171.
38. Lemere C.A., Blustzjan J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid-β peptides and Apo E in down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:1996;16-32.
39. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R.et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N.Y. Acad. Sci. 920:2000;328-331.
40. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:1992;2277-2281.
41. Mason H., Ball J., Shi J.J., Jiang X., Estes M., Arntzen C. Expression of Norwalk virus capsid protein in transgenic tobacco and potato plants and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5335-5340.
42. McCluski M., Weeratna R., Clements J., Davis H. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine. 19:2001;3759-3768.
43. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161(9):1998;4463-4466.
44. McNeal M., Rae M., Bean J., Ward R. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles. J. Virol. 73:1999;7565-7573.
45. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J.et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):2000;982-985.
46. Morris C.B., Cheng E., Thanawastien A., Clements J.D. Effectiveness of intranasal immunization with HIV-gp160 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine. 18:2000;1944-1951.
47. O'Neal C., Clements J., Estes M., Conner M. Rotavirus 2/6 virus-like particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT(R192G) induce protection from rotavirus challenge [in process citation]. J. Virol. 72:1998;3390-3393.
48. Pierce N.S., Gowans J.L. Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J. Exp. Med. 142:1975;1550-1563.
49. Ryan E.J., McNeela E., Murphy G.A., Stewart H., O'Hagan D., Pizza M.et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the non-toxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67(12):1999;6270-6280.
50. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C., Glenn G. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:2000;5306-5313.
51. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
52. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399(Supp):1999;A23-A31.
53. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:2001;439-447.
54. Solomon B., Koppel R., Frenkel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 94:1997;4109-4112.
55. Solomon B., Koppel R., Hanan E., Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. U.S.A. 93:1996;452-455.
56. Staats H., Nichols W., Palker T. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP 10 MN(A). J. Immunol. 157:1996;462-472.
57. Tamura S., Yajima A., Hatori E., Asanuma H., Suzuki Y., Aizawa C.et al. Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection. Vaccine. 15(16):1997;1784-1790.
58. Town T., Tan J., Sansone N., Obregon D., Klein T., Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42. Neurosci. Lett. 307:2001;101-104.
59. Tumpey T., Renshaw M., Clements J., Katz J. Mucosal delivery of inactivated influenza vaccine induces B cell-dependent heterosubtypic cross-protection against lethal A H5N1 virus infection. J. Virol. 75:2001;5141-5150.
60. VanCott T.C., Kaminski R.W., Mascola J.R., Kalyanaraman V.S., Wassef N.M., Alving C.R.et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160(4):1998;2000-2012.
61. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C.et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48(4):2000;567-579.
62. Weltzin R., Kleanthous H., Guirakhoo F., Monath T., Lee C. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine. 4:1997;370-376.
63. Wu Y-Y., Nahm M., Guo Y., Russell M., Briles D. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:1997;839-846.
64. Xu-Amano J., Jackson R., Fujihashi K., Kiyono H., Staats H., McGhee J. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine. 12:1994;903-911.
65. Xu-Amano J., Kiyono H., Jackson R., Staats H., Fujihashi K., Burrows P.et al. Helper Th1 and Th2 cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa-associated tissues. J. Exp. Med. 178:1993;1309-1320.
66. Yamamoto M., Vancott J., Okahashi N., Marinaro M., Kiyono H., Fujihashi K.et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann. N.Y. Acad. Sci. 778:1996;64-71.
67. Yuan L., Geyer A., Hodgins D., Fan Z., Qian Y., Chang K.et al. Intranasal administration of 2/6 rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT(R192G)) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J. Virol. 74:2000;8843-8853.